P&G to Acquire Thorne for $3.8 Billion: What It Means for the Supplements You Trust

Procter & Gamble signed a definitive agreement on August 4, 2026 to acquire Thorne — the third-party-tested supplement brand many of you rely on for magnesium, creatine, and methylated B vitamins — for $3.8 billion. The deal is confirmed, not rumored: P&G CEO Shailesh Jejurikar announced it on CNBC, and Thorne's own press release backs it up. Thorne's current owner, private equity firm L Catterton, sold to P&G after fielding competing bids from Haleon and Unilever.

Here's the short version: nothing changes for you today. The deal hasn't closed yet — it's pending regulatory approval and is expected to close later this year. Thorne's affiliate and ambassador program terms are unchanged as of this writing. But a $3.8 billion acquisition by a consumer packaging giant is the kind of event that reshapes a brand over the following 12-18 months, and if you've built any part of your supplement stack around Thorne, it's worth understanding what's actually at stake.

What Actually Happened

L Catterton, the private equity firm that has owned Thorne since 2018, had been fielding acquisition interest since at least late June 2026. Early reporting (via the Financial Times and Axios) pegged the deal at up to $4 billion, with Haleon — the consumer health spinoff of GSK — reported as the frontrunner for most of July. Unilever was also in the mix.

P&G entered late and won. The final number landed at $3.8 billion, and the deal was announced as a definitive agreement, meaning both sides have signed and are contractually committed, subject to regulatory sign-off. That's a meaningfully different situation from the "sources say" reporting that circulated for most of the summer — this is now a matter of public record, confirmed by the CEO of the acquiring company.

For context on why P&G wanted Thorne specifically: Thorne has spent two decades building a reputation most competitors envy — NSF Certified for Sport testing across its athletic line, ISO-certified manufacturing, and a direct-to-consumer and practitioner-channel distribution model that reaches health-focused consumers P&G's traditional retail brands (Old Spice, Crest, Pantene) don't touch. For a company built on mass retail, buying a premium, trust-driven wellness brand is a fast way into a category growing much faster than P&G's legacy business.

The Bidding War, In Brief

This deal didn't come together overnight, and the back-and-forth is worth understanding because it explains why P&G was willing to pay a premium.

The first reports of a potential sale surfaced in late June 2026, with early coverage from the Financial Times (via Yahoo Finance and Axios) putting a potential deal at up to $4 billion. At that point, no single bidder had pulled ahead — L Catterton was running a competitive process with multiple consumer health and CPG companies circling.

By late July, Haleon — the standalone consumer health company spun off from GSK in 2022, known for brands like Sensodyne and Centrum — was reported to be "nearing a deal" for Thorne. For a stretch of about a month, most industry chatter assumed Haleon would be the winner. Unilever remained a secondary bidder throughout, and P&G entered the process later but with the financial position to outbid both.

Then the story went quiet. A check in late July found no new developments for nearly a month — every source still traced back to the same original reporting chain, with no confirmation from any of the four companies involved. That kind of silence in an active deal process usually means final terms are being negotiated behind closed doors, which is exactly what played out: P&G closed the gap and signed a definitive agreement on August 4, beating Haleon's earlier positioning.

Why P&G Wanted Thorne Specifically

It's worth asking why a company known for Tide, Gillette, and Crest wants a $3.8 billion supplement brand. The answer says something about where the entire wellness industry is heading.

P&G's traditional retail categories — laundry, grooming, oral care — are mature, low-growth markets. Consumer wellness and personalized health, by contrast, has been one of the fastest-growing segments in consumer goods for the better part of a decade, driven by exactly the kind of health-optimization-minded, evidence-seeking consumer that reads a site like this one. P&G has made smaller moves into this space before, but Thorne represents a much larger, more direct bet: buying an established brand with existing trust, testing infrastructure, and distribution, rather than building one from scratch.

That trust is the asset. Thorne's NSF Certified for Sport testing, ISO-certified manufacturing, and practitioner-channel relationships took nearly two decades to build. P&G's retail scale and marketing budget could, in theory, get Thorne products in front of a far larger audience than the direct-to-consumer and practitioner channels have reached on their own. Whether that scale-up preserves what made Thorne trustworthy in the first place is the open question — and it's the same question every acquired premium brand faces once it's inside a larger portfolio.

How This Compares to Past Supplement Industry Acquisitions

This isn't the first time a mass-market consumer company has bought a premium, testing-forward supplement brand, and the track record is genuinely mixed. In some cases, acquired brands retained their manufacturing standards and simply gained distribution and marketing muscle — a net win for consumers who wanted easier access. In others, formulations were quietly adjusted, price points shifted to hit new margin targets, or the acquired brand's practitioner-first identity got diluted as it moved into mass retail.

The honest takeaway: acquisition alone doesn't tell you which path a brand will take. What matters is what happens in the 6-18 months after close — whether testing certifications are maintained, whether founder or scientific leadership stays on, and whether pricing and formulation stay consistent. That's exactly why we're building this into our recheck cadence rather than treating today's announcement as the end of the story.

What This Means If You Use Thorne Products

Your current orders and subscriptions are unaffected. Deals like this take months to close and even longer to integrate. Formulations, testing standards, and pricing haven't changed and won't change overnight even after closing.

Quality standards are the thing to watch, not the thing to panic about. Thorne's competitive advantage — the reason we've recommended it across magnesium, creatine, and B-complex — is rigorous third-party testing and clean-label manufacturing. For a full breakdown of where Thorne's testing standards actually land versus other brands we recommend, see our supplement brand comparison guide. Acquirers generally don't gut the thing they just paid a premium for. P&G paid $3.8 billion specifically because of Thorne's trust and quality reputation; undermining that in year one would be destroying the asset they bought. That said, "generally don't" isn't "never" — we've watched enough acquisitions to know integration decisions can surprise everyone, including the acquirer's own leadership.

Pricing is the more realistic near-term risk. Large consumer goods companies often push acquired premium brands toward broader retail distribution — think Costco, Target, or Walmart shelf space instead of purely direct-to-consumer and practitioner channels. That can mean wider availability (good for accessibility) but sometimes comes with formulation adjustments to hit lower price points or manufacturing cost targets (worth watching for).

Affiliate and ambassador program terms have not changed. Thorne currently runs a tiered commission structure that rewards long-term recommenders, and nothing in the P&G announcement addresses that program. We'll flag it immediately if that changes, since it would affect how we can continue recommending Thorne products going forward.

Why We're Telling You Now, Not Waiting

We could wait until the deal closes and details firm up. We're not, for a simple reason: you deserve to know about material changes to brands you've trusted with your health budget as soon as we have confirmed information, not after the fact. This is confirmed news as of August 4, 2026 — not speculation — and it's directly relevant to anyone with Thorne products in their stack.

It's also worth saying plainly: VitalStack's content and recommendations are not written to protect any single brand relationship. If Thorne's quality standards, pricing, or availability change in ways that affect the products we recommend, we'll update our guides and, if warranted, change our recommendations. That commitment doesn't change because of who owns the company.

What to Watch Over the Next 6-12 Months

If you want to track this yourself rather than waiting for us to update you, here's what actually matters:

• Regulatory approval and close date. Large acquisitions like this typically face antitrust review. A close date will be the first real milestone — expect it sometime in late 2026 based on P&G's public timeline.
• Manufacturing and testing disclosures. Watch Thorne's own site and third-party testing certifications (NSF Certified for Sport, in particular) for any changes in language or scope.
• Formulation changes. If a product's label or ingredient sourcing changes, that's usually disclosed on the product page or in a reformulation notice. Compare against what you're used to if you're a long-time user.
• Distribution shifts. If Thorne starts appearing on major retail shelves at different price points than its direct-to-consumer pricing, that's a signal integration is underway.
• Leadership departures. Founder and executive departures after an acquisition are often the clearest early signal of how much operational control the acquirer intends to exert.

Should You Change What's in Your Stack Right Now?

No. There's no product recall, no reformulation, and no quality issue tied to this news — it's a corporate ownership change, not a product change. If you currently use Thorne Magnesium Bisglycinate, Thorne Creatine, or any other Thorne product as part of your protocol, there's no reason to stop or switch based on today's announcement alone.

What we'd suggest instead: don't over-index your entire stack on a single brand regardless of what happens with Thorne. That's sound practice independent of this news — third-party testing and ingredient transparency matter more than the logo on the label, and several other brands (Pure Encapsulations, Designs for Health, NOW Foods) meet similar testing standards if you ever need to diversify. If you're building out a broader protocol rather than swapping one brand for another, our best magnesium supplements and best methylated B-complex supplements guides both cover multiple third-party-tested options beyond Thorne, and our general supplement recommendations roundup is a good starting point if you're rethinking your stack from scratch.

We'll be tracking this story closely and will update this article and our product guides the moment there's a confirmed change to Thorne's formulations, pricing, or program terms.

Frequently Asked Questions

Is the P&G-Thorne deal final?

Not yet. It's a signed, definitive agreement — meaning both companies are contractually committed — but it still needs to clear regulatory approval before it officially closes. P&G has indicated the deal is expected to close later in 2026.

Will Thorne products get more expensive?

There's no confirmed pricing change as of this writing. The realistic risk isn't an immediate price hike — it's a longer-term shift in distribution strategy that could affect where and how Thorne products are sold. We'll flag any confirmed pricing changes as soon as they're announced.

Should I stop using Thorne supplements?

No. This is an ownership change, not a product recall or quality issue. Current formulations, testing standards, and manufacturing are unaffected by today's announcement. If that changes post-close, we'll tell you directly.

Does this affect other supplement brands VitalStack recommends?

Not directly. This acquisition is specific to Thorne. We recommend other third-party-tested brands like Pure Encapsulations and Designs for Health independently of this news, and that hasn't changed.

Where did this information come from?

P&G CEO Shailesh Jejurikar confirmed the definitive agreement on CNBC on August 4, 2026, and Thorne issued its own press release confirming the deal terms. This is not based on anonymous sourcing or rumor — both companies have gone on record.

Last updated: 2026-08-05

---